ZYME
AI MemoPost-earnings T+3Zymeworks
As of 2026-08-08/Post-earnings T+3/Confidence medium
Data freshness
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Decision Panel
Action, confidence, horizon, and decision blockers at a glance.
Action
—
Confidence
medium
Horizon
—
Key catalyst
FDA PDUFA decision for zanidatamab • 2026-08-25
Base target: $31 / p=50% prob
Biggest risk
The thesis remains event-driven: FDA approval, the acquisition closing, and clinical updates are not assured. The company did not host a Q2 earnings call, and the packet contains no verified post-print consensus surprise, analyst estimate revision, or target change. Clinical, regulatory, integration, and cash-flow execution risks therefore remain material.
Invalidation
Break below $16 or thesis failure.
What would change my mind?
The bull case rests on the August zanidatamab regulatory decision, potential milestone and royalty expansion, the planned Theravance closing, and additional partnered or wholly owned pipeline catalysts. The Q2 release also described a $322.5 million liquidity position and continued capital returns. [#SEC-8K-2026-08-06]
Research note
Recommendation
—
Confidence
medium
As of
2026-08-08
Base target
$31
p=50%
Bull target
$42
p=25%
Bear target
$16
p=25%
Key bullets
Fast scan of bull, bear, and watch items
BullKey bullets
- HERIZON-GEA-01 overall-survival update
- Partnered pasritamig development update
- The bull case rests on the August zanidatamab regulatory decision, potential milestone and royalty expansion, the planned Theravance closing, and additional partnered or wholly owned pipeline catalysts.
BearKey bullets
- FDA delay, rejection, or restrictive labeling for zanidatamab could eliminate or defer the potential milestone and royalty uplift.
- HERIZON-GEA-01 and other pipeline readouts may disappoint or be delayed.
- Low coverage and a loose peer set reduce confidence in valuation triangulation.
WatchKey bullets
- FDA PDUFA decision for zanidatamab
Summary
High-level snapshot
Recommendation
-
Model confidence
medium
Timeframe
-
Asset
Equity
Trigger
Post-earnings T+3
Base case: $31 (p=50%)
Target spread vs base: +35% / -48%
Scenario probabilities
Bull Target: $42 (p=25%)Base Target: $31 (p=50%)Bear Target: $16 (p=25%)
Commentary
News tone is mixed-positive because the earnings release highlighted multiple second-half catalysts, the Theravance transaction, and capital returns, while external coverage framed the acquisition more cautiously. Social, options, short-interest, and employee data were unavailable. Consensus surprise, post-print target or estimate revisions, and a quantified price reaction were also unavailable; the 2026-08-06 anchor price should not be interpreted as evidence of a favorable earnings reaction.
As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology
Analyst Summary
Thesis highlights from the latest analysis
Bull Case
The bull case rests on the August zanidatamab regulatory decision, potential milestone and royalty expansion, the planned Theravance closing, and additional partnered or wholly owned pipeline catalysts. The Q2 release also described a $322.5 million liquidity position and continued capital returns. [#SEC-8K-2026-08-06]
Bear Case
The thesis remains event-driven: FDA approval, the acquisition closing, and clinical updates are not assured. The company did not host a Q2 earnings call, and the packet contains no verified post-print consensus surprise, analyst estimate revision, or target change. Clinical, regulatory, integration, and cash-flow execution risks therefore remain material.
Drivers
Scannable catalysts and supporting factors
- HERIZON-GEA-01 overall-survival update
- Partnered pasritamig development update
Scenarios
Bull Target (Scenario probability)
$42 / p=25% prob
Base Target (Scenario probability)
$31 / p=50% prob
Bear Target (Scenario probability)
$16 / p=25% prob
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Analysis reference price unavailable. Targets are shown without scenario returns.
Sentiment & Exposure
News Sentiment (30d)
0.25
Social Sentiment (7d)
0.00
Events
Other notable items detected
- EVENT2026-08-25FDA PDUFA decision for zanidatamabThe August 25, 2026 U.S. PDUFA date for first-line HER2-positive GEA could unlock a $250 million approval milestone and support additional royalty and regulatory cash flows. [#SEC-8K-2026-08-06]Prob 65.00% • Move 20.00% • Priced-in 55.00%
- EVENT2026-11-06Q2 2026 release confirms royalty base and liquidityThe August 6 release reported $1.8 million of Q2 royalty revenue, $322.5 million of cash, cash equivalents and marketable securities at June 30, and $49.4 million of share repurchases through August 4. Consensus surprise, analyst revisions, and quantified post-print price reaction were unavailable. [#SEC-8K-2026-08-06]Prob 100.00% • Move 2.00% • Priced-in 80.00%
- EVENT2026-11-06Theravance acquisition closingZymeworks expects the proposed Theravance Biopharma acquisition to close in the second half of 2026, subject to regulatory approval and customary closing conditions, adding commercial cash flows to the portfolio. [#SEC-8K-2026-08-06]Prob 70.00% • Move 10.00% • Priced-in 50.00%
Short-term Catalysts
Next few weeks
No short-term catalysts
Long-term Catalysts
Months to a year
- HERIZON-GEA-01 overall-survival update2027-08-08Top-line results from the second interim overall-survival analysis for the zanidatamab doublet regimen are expected in Q3 2026, creating a clinically meaningful but binary data point. [#SEC-8K-2026-08-06]Prob 55% • Move 12% • Priced-in 35%
- Partnered pasritamig development update2027-08-08Johnson & Johnson expects Phase 1b pasritamig data in the second half of 2026; the Phase 3 program has increased planned enrollment to 1,203 participants and is actively recruiting. [#SEC-8K-2026-08-06]Prob 50% • Move 8% • Priced-in 25%
Risks
- FDA delay, rejection, or restrictive labeling for zanidatamab could eliminate or defer the potential milestone and royalty uplift.
- HERIZON-GEA-01 and other pipeline readouts may disappoint or be delayed.
- Low coverage and a loose peer set reduce confidence in valuation triangulation.
- The Q2 packet does not provide a verified revenue or EPS consensus comparison, post-print analyst revision signal, or quantified market reaction.
- The Theravance transaction remains subject to regulatory approval and customary closing conditions, with integration and financing execution risk.
Peers
| Symbol | Summary |
|---|---|
| AAPG | Similar-sector and similar-market-cap screening candidate, but the packet provides no indication-level evidence establishing it as a clean operating comparable. |
| IMCR | Similar-sector, similar-scale biopharma candidate; useful for broad sentiment context, but pipeline and commercial comparability remain limited. |
Sources
Internal and external references used in this analysis
- Model source: RankAlpha Sentiment Codex
- Analysis date: 2026-08-08